AroCell
0,51 SEK 0%2 investorer følger denne virksomhed
AroCell specializes in oncology and bacteriology. The company has a broad product portfolio, and develops, markets and sells blood and urine sample tests that are used by hospitals and clinics. The tests are intended to provide information for the detection of diseases such as urological cancers and typhoid fever. AroCell targets patient groups in different parts of the world. The head office is in Stockholm.
Omsætning
43,04 mio.
EBIT %
-138,89 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
AROC
Daglig lav / høj pris
0,496 / 0,555
SEK
Markedsværdi
117,48 mio. SEK
Aktieomsætning
24,35 t SEK
Volumen
47 t
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Labbex Förvaltnings AB | 11,6 % | 11,6 % |
Avanza Pension | 8,9 % | 8,9 % |
Greg Dingizian | 6,8 % | 6,8 % |
Jon Eiken | 3,9 % | 3,9 % |
Nordnet Pensionsförsäkring | 2,8 % | 2,8 % |
Mikael Jacobsson | 2,0 % | 2,0 % |
Mikael Lönn | 1,9 % | 1,9 % |
Gunvald Berger | 1,6 % | 1,6 % |
Didrik Hamilton | 1,4 % | 1,4 % |
Gerhard Dal | 1,3 % | 1,3 % |
ViserAlle indholdstyper
Redeye: AroCell Q3 - Robust sales growth and cost control
AroCell AB (publ) Interim Report January 1st to September 30th, 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools